Display options
Cite
Simbiri KO, Jha HC, Kayembe MK, et al. Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana. Infect Agent Cancer. 2014;9:28doi: 10.1186/1750-9378-9-28.
Simbiri, K. O., Jha, H. C., Kayembe, M. K., Kovarik, C., & Robertson, E. S. (2014). Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana. Infectious agents and cancer, 928. https://doi.org/10.1186/1750-9378-9-28
Simbiri, Kenneth O, et al. "Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana." Infectious agents and cancer vol. 9 (2014): 28. doi: https://doi.org/10.1186/1750-9378-9-28
Simbiri KO, Jha HC, Kayembe MK, Kovarik C, Robertson ES. Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana. Infect Agent Cancer. 2014 Aug 24;9:28. doi: 10.1186/1750-9378-9-28. eCollection 2014. PMID: 25225572; PMCID: PMC4164322.
Copy Download .nbib Format: NLM
Share it on

Infect Agent Cancer. 2014 Aug 24;9:28. doi: 10.1186/1750-9378-9-28. eCollection 2014.

Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana.

Infectious agents and cancer

Kenneth O Simbiri, Hem C Jha, Mukendi K Kayembe, Carrie Kovarik, Erle S Robertson

Affiliations

  1. Department of Microbiology and Immunology, Upstate Medical University, R2120A, Weiskotten Hall, 750 East Adams Street, Syracuse, NY 13210, USA.
  2. Department of Microbiology, Abramson Cancer Center, Tumor Virology Program, Perelman School of Medicine at the University of Pennsylvania, 202A Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104-6076, USA.
  3. National Health Laboratory, Gaborone, Botswana.
  4. Botswana-University of Pennsylvania Partnership, Gaborone, Botswana ; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

PMID: 25225572 PMCID: PMC4164322 DOI: 10.1186/1750-9378-9-28

Abstract

BACKGROUND: Oncoviruses such as HPV, KSHV, and EBV have been reported in patients with HIV infection and AIDS. How oncovirus-associated cancers rise in AIDS patients has not been fully established. The purpose of our study was to identify the viral agents in vulvar cancer and to assess their contribution to pathogenesis.

METHOD: We retrospectively identified a total of 13 vulva tissue samples from HIV-1 positive and 9 vulvar samples from HIV-1 negative patients from the Botswana National Health Laboratory in Gaborone, Botswana, a Southern African country with a high incidence of HIV. We utilized PCR and IHC to identify HPV, EBV, KSHV, and JC virus in FFPE preserved tissue samples.

RESULTS: Using the GP5(+)/GP6(+) primer set we detected several HPV types in tissue samples. EBV was detected in all of the positive cases (100%) and in most of the negative cases (89%). KSHV was detected in 39% of the HIV-1 positive samples and in 11% of the negative samples, and no JC virus was detected in any of the samples. Using IHC we demonstrated that LANA was expressed in 61% of the positive samples and in 44% of the negative samples. The ubiquitous EBV was more consistently expressed in negative cases (100%) than in positive cases (69%). Interestingly, the HPV-16 E6 transcript was detected in 56% of the negative samples compared to 31% of the positive samples. However, the cell cycle protein P21 used as a surrogate marker for HPV was detected in 77% of the positive samples and in 44% of the negative samples, while VEGF signals were similar in both positive (92%) and negative samples (89%).

CONCLUSION: Our study, suggests that in Botswana, vulvar squamous cell carcinoma (VSCC) is associated with oncogenic viruses present in the niche but the contribution and progression may be regulated by HPV and other immunosuppressive infections that include HIV-1.

Keywords: EBV; HIV-1; HPV; KSHV; OSSN

References

  1. J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 - PubMed
  2. Br J Ophthalmol. 1997 Apr;81(4):308-13 - PubMed
  3. Int J Gynecol Cancer. 2001 Sep-Oct;11(5):381-6 - PubMed
  4. Bull Cancer. 2013 Feb 1;100(2):141-6 - PubMed
  5. PLoS One. 2010 Jan 11;5(1):e8621 - PubMed
  6. J Med Virol. 2002 Mar;66(3):351-9 - PubMed
  7. Oncology. 2005;69 Suppl 3:4-10 - PubMed
  8. J Natl Cancer Inst. 1997 Oct 15;89(20):1516-23 - PubMed
  9. Ghana Med J. 2012 Sep;46(3):142-6 - PubMed
  10. Nat Rev Cancer. 2009 Jun;9(6):400-14 - PubMed
  11. BMC Cancer. 2013 Oct 29;13:506 - PubMed
  12. Eur J Gynaecol Oncol. 1999;20(2):111-4 - PubMed
  13. Niger J Med. 2011 Apr-Jun;20(2):266-9 - PubMed
  14. J Clin Microbiol. 2000 Sep;38(9):3274-9 - PubMed
  15. Gynecol Oncol. 2008 Jun;109(3):340-5 - PubMed
  16. J Pathol. 1992 Dec;168(4):357-63 - PubMed
  17. AIDS. 2005 Sep 2;19(13):1407-14 - PubMed
  18. Mod Pathol. 1990 Jul;3(4):442-8 - PubMed
  19. Int J Cancer. 2000 Nov 1;88(3):489-92 - PubMed
  20. Clin Cancer Res. 1999 Oct;5(10):2806-9 - PubMed
  21. Clin Diagn Lab Immunol. 2003 Jan;10(1):66-9 - PubMed
  22. Curr Opin Obstet Gynecol. 1992 Aug;4(4):582-5 - PubMed
  23. Afr J Med Med Sci. 1999 Mar-Jun;28(1-2):77-80 - PubMed
  24. J Clin Microbiol. 1996 Mar;34(3):745-7 - PubMed
  25. Eur J Gynaecol Oncol. 2006;27(4):405-8 - PubMed
  26. Pathologe. 2011 Nov;32(6):467-75 - PubMed
  27. Antivir Ther. 2004 Feb;9(1):13-22 - PubMed
  28. Front Biosci (Schol Ed). 2011 Jan 01;3:136-44 - PubMed
  29. Diagn Mol Pathol. 1995 Dec;4(4):239-48 - PubMed
  30. Obstet Gynecol. 1992 Mar;79(3):448-54 - PubMed
  31. J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 - PubMed
  32. Infect Agent Cancer. 2010 Mar 26;5:6 - PubMed

Publication Types

Grant support